Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Omega 3 Prescription Drugs Market Size Forecast: How Big Could The Market Get By 2030?
The omega 3 prescription drugs market has witnessed robust expansion in recent years. This market is set to increase from $1.75 billion in 2025 to $1.92 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.9%. The historical progression can be linked to the significant occurrence of hypertriglyceridemia, a heightened awareness regarding cardiovascular diseases, the expanding elderly population, the presence of prescription omega-3 medications, and an increase in clinical research and trials.
The omega 3 prescription drugs market size is expected to experience substantial growth in the upcoming years. It is projected to reach $2.81 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 10.0%. The expansion during this forecast period is largely attributed to progress in precision medicine, an increasing demand for personalized treatments, the incorporation of digital health tools, a broadening presence in developing markets, and innovations in omega-3 drug compositions. Noteworthy trends anticipated for this period encompass the development of personalized omega-3 therapies, a rise in clinical trials for omega-3 formulations, the proliferation of solutions for managing cardiovascular risks, improved access to prescribed omega-3 medications, and stronger integration between nutraceuticals and pharmaceuticals.
Get A Free Sample Report With In-Depth Market Insights:
Omega 3 Prescription Drugs Market Industry Drivers: What’s Behind The Revenue Growth?
The increasing number of cardiovascular disease (CVD) cases is anticipated to contribute to the growth of the omega-3 prescription drug market. Elevated blood triglyceride levels, a fatty-like substance, are associated with a higher risk of cardiovascular disorders, and omega-3 supplements assist in regulating and reducing these triglyceride levels. For example, the National Institutes of Health, a US-based government agency, indicated in August 2025 that between 2025 and 2050, cardiovascular prevalence is projected to rise by 90%, mortality by 73%, and DALYs by 55%, with deaths increasing from 20.5 million to 35.6 million. Thus, the growing prevalence of cardiovascular diseases (CVDs) drives the expansion of the omega-3 prescription drug market.
Omega 3 Prescription Drugs Market Segment Landscape: Which Areas Lead Development?
The omega 3 prescription drugs market covered in this report is segmented –
1) By Drug Type: Vascepa, Lovaza, Other Type
2) By Application Type: Hypertriglyceridemia, Other Application Type
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Vascepa: Pure EPA (Eicosapentaenoic Acid) Formulation, Indications For Cardiovascular Risk Reduction
2) By Lovaza: Combination Of EPA And DHA (Docosahexaenoic Acid), Indications For Hypertriglyceridemia Management
3) By Other Types: Epanova (Omega-3 Carboxylic Acids), Omega-3 Formulations In Clinical Trials, Other Prescription Omega-3 Products
#Omega 3 Prescription Drugs Market Growth Trends: What’s Shaping The Future Outlook?
Leading companies in the omega-3 prescription drug market are concentrating on introducing products, specifically capsules, designed to reduce the body’s triglyceride production. Capsules are dosage forms for pharmaceuticals or dietary supplements, typically featuring a shell, often made of gelatin or a similar material, that encloses a precise amount of medication, nutrients, or other active components for convenient and easy ingestion. For example, in March 2023, Hikma Pharmaceuticals, an England-based multinational pharmaceutical company that manufactures generic and in-licensed pharmaceutical products, launched Icosapent Ethyl Capsules, 0.5g, in the US. This product is indicated for lowering triglyceride levels in adults with severe hypertriglyceridemia and contains eicosatetraenoic acid (EPA), known for its triglyceride-reducing effects. This launch contributes to market innovation by addressing severe hypertriglyceridemia, fulfilling the increasing demand for pharmaceutical-grade omega-3 products, and aligning with the market’s emphasis on effective treatments for conditions like high triglyceride levels.
Omega 3 Prescription Drugs Market Industry Leaders And Competitive Landscape
Major companies operating in the omega 3 prescription drugs market are Pfizer Inc., Sanofi S.A., Amarin Corporation plc, GlaxoSmithKline plc, AstraZeneca plc, Merck & Co. Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, BASF SE, DSM Nutritional Products, AbbVie Inc., Eli Lilly and Company, Bayer AG, Shire Pharmaceuticals, Mylan NV, Teva Pharmaceutical Industries Ltd., Horizon Therapeutics, Kyowa Kirin Co. Ltd., Sumitomo Pharma Co. Ltd.
View The Full Omega 3 Prescription Drugs Market Report:
Omega 3 Prescription Drugs Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the omega 3 prescription drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the omega 3 prescription drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model